4.4 Article

Sex-Dependent Staging in Non-Small-Cell Lung Cancer; Analysis of the Effect of Sex Differences in the Eighth Edition of the Tumor, Node, Metastases Staging System

期刊

CLINICAL LUNG CANCER
卷 19, 期 6, 页码 E933-E944

出版社

CIG MEDIA GROUP, LP
DOI: 10.1016/j.cllc.2018.08.004

关键词

Gender; Lung cancer; Surgical oncology; Thoracic surgery; Tumor staging

类别

向作者/读者索取更多资源

Because men with lung cancer have poorer survival, we examined the effect of sex on the prognostic value of the eighth edition of tumor, node, metastases staging (TNM). Men had worse 5-year survival within each stage. This suggests that outcomes in TNM staging should be quoted separately for men and women to improve the prognostic, research, and clinical accuracy. Introduction: Non-small-cell lung cancer (NSCLC) has disproportionately negative outcomes in men compared with women. The importance of the relationship between sex and tumor, node, metastases (TNM) staging system remains unknown. The objective of this study was to investigate the effect of sex on NSCLC survival for each stage in the eighth edition of the TNM staging system in NSCLC. Patients and Methods: Two cohorts treated surgically with curative intent between 2000 and 2010 were analyzed. The primary cohort was from Australia with a second population set from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate analyses of putative and validated prognostic factors were undertaken to investigate sex-dependent prognostication with detailed analyses of sex differences in each TNM stage. The primary outcome was disease-specific survival (DSS) at 5 years. Results: Inclusion criteria were met by 555 patients in the Australian cohort, 335 men (60.4%) and 220 (39.6%) women; and 47,706 patients from the SEER cohort, 24,671 men (51.7%) and 23,035 women (48.3%). Five-year DSS was significantly worse for men in multivariate analyses for the Australian (hazard ratio [HR], 1.44; 95% confidence interval [CI], 1.04-1.98; P - .026) and SEER (HR, 1.24; 95% CI, 1.20-1.28; P < .001) cohorts. Detailed analysis of TNM stage sex differences revealed a consistent pattern of men having worse survival than women across stages in both cohorts. Conclusion: The poorer survival in men with NSCLC presents research and clinical communities with an important challenge. This study's findings suggest that for men and women diagnosed with NSCLC, and managed surgically, stage-specific outcomes should be quoted separately and consideration to a rapid prognostic score with sex combined with staging as a key element. (C) 2018 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Women with gynaecological cancer awaiting radiotherapy: Self-reported wellbeing, general psychological distress, symptom distress, sexual function, and supportive care needs

Karla Gough, Rebecca Jane Bergin, Allison Drosdowsky, Sanchia Aranda, Linda Mileshkin, Michael Jackson, Nicole Kinnane, David Bernshaw, Ilona Juraskova, Kate White, Mustafa Mohamed, Penelope Schofield

Summary: Before commencing curative radiotherapy, a substantial minority of women with gynaecological cancers experience general psychological distress, reduced wellbeing, and moderate-to-high health system and information needs. A model of comprehensive care incorporating assessment of unmet needs, general psychological distress, and sexual issues is recommended. Health care providers may require training to address these interrelated issues and provide relevant support services for women in need.

GYNECOLOGIC ONCOLOGY (2022)

Article Health Care Sciences & Services

Social return on investment economic evaluation of supportive care for lung cancer patients in acute care settings in Australia

Amelia Hyatt, Holly Chung, Ruth Aston, Karla Gough, Meinir Krishnasamy

Summary: This study utilized the SROI methodology to evaluate the social value and return on investment of lung cancer supportive care services, and found that cost savings could be achieved through implementation of the proposed supportive care service model.

BMC HEALTH SERVICES RESEARCH (2022)

Article Oncology

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study

Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, Sumi Ananda, Niall C. Tebbutt, Michael Michael, Emma Link, Stephen Q. Wong, Sushma Chandrashekar, Jerick Guinto, David Ritchie, Rachel Koldej, Benjamin J. Solomon, Grant A. McArthur, Rodney J. Hicks, Peter Gibbs, Sarah-Jane Dawson, Jayesh Desai

Summary: BRAF V600E mutant metastatic colorectal cancer is a significant clinical problem. Combination therapy with vemurafenib and small-molecule EGFR inhibitors has shown effectiveness in pre-clinical studies, but clinical investigation is lacking.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

Refocusing cancer supportive care: a framework for integrated cancer care

Meinir Krishnasamy, Amelia Hyatt, Holly Chung, Karla Gough, Margaret Fitch

Summary: Cancer supportive care is a comprehensive field of multidisciplinary services aimed at helping individuals affected by cancer manage the challenges of their disease and treatment to achieve optimal health outcomes. This study aimed to examine contemporary expert views on supportive care and redefine its definition and conceptual framework to better align with current cancer care practices.

SUPPORTIVE CARE IN CANCER (2023)

Editorial Material Oncology

Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer

Benjamin J. Solomon, Todd M. Bauer, Tony S. K. Mok, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Yi-Long Wu, Jacek Jassem, Froylan Lopez Lopez, Ross A. Soo, Alice T. Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip

FUTURE ONCOLOGY (2023)

Editorial Material Oncology

Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer

Trudy C. Wu, Annalise Stube, Carol Felix, Denise Oseguera, Tahmineh Romero, Jonathan Goldman, Edward B. Garon, Jay M. Lee, John Glaspy, Aaron E. Lisberg, Chad G. Rusthoven, D. Ross Camidge, Shankar Siva, Benjamin Solomon, Alan Lee, Stephen E. Tenn, Narek Shaverdian, Michael L. Steinberg, Ann C. Raldow, Percy Lee

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Letter Oncology

Response to Letter to the Editor From Binghao Zhao et al

Nicolas Girard, Marina C. Garassino, Benjamin Solomon

JOURNAL OF THORACIC ONCOLOGY (2023)

Letter Oncology

About Clinical Significance of Lung-RADS Category 3 Lesions

Nicolas Girard, Marina C. Garassino, Benjamin Solomon

JOURNAL OF THORACIC ONCOLOGY (2023)

Article Oncology

Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC

Ross A. Soo, Jean-Francois Martini, Anthonie J. van der Wekken, Shunsuke Teraoka, Roberto Ferrara, Alice T. Shaw, Deborah Shepard, Anna Maria Calella, Anna Polli, Francesca Toffalorio, Pascale Tomasini, Chao-Hua Chiu, Dariusz M. Kowalski, Hye Ryun Kim, Benjamin J. Solomon

Summary: In treatment-naive patients with advanced ALK-positive NSCLC, ctDNA can be used as a biomarker to predict the efficacy of lorlatinib treatment.

JOURNAL OF THORACIC ONCOLOGY (2023)

Article Medicine, General & Internal

Sotorasib versus docetaxel for previously treated non-small- cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Adrianus Johannes de Langen, Melissa L. Johnson, Julien Mazieres, Anne -Marie C. Dingemans, Giannis Mountzios, Miklos Pless, Jurgen Wolf, Martin Schuler, Herve Lena, Ferdinandos Skoulidis, Yasuto Yoneshima, Sang-We Kim, Helena Linardou, Silvia Novello, Anthonie J. van der Wekken, Yuanbin Chen, Solange Peters, Enriqueta Felip, Benjamin J. Solomon, Suresh S. Ramalingam, Christophe Dooms, Colin R. Lindsay, Carlos Gil Ferreira, Normand Blais, Cynthia C. Obiozor, Yang Wang, Bhakti Mehta, Tracy Varrieur, Gataree Ngarmchamnanrith, Bjorn Stollenwerk, David Waterhouse, Luis Paz-Ares

Summary: This study compared the efficacy and safety of Sotorasib with standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRASG12C mutation. The results showed that compared to docetaxel, Sotorasib significantly increased progression-free survival and had a more favorable safety profile.

LANCET (2023)

Review Oncology

Optimal first-line treatment for metastatic ALK plus non-small cell lung cancer-a narrative review

Grace Chazan, Benjamin J. Solomon

Summary: First-line treatment options for patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbour anaplastic lymphoma kinase (ALK) gene rearrangements have evolved rapidly. Although newer generation ALK inhibitors have demonstrated superiority to crizotinib, head-to-head clinical trials comparing these inhibitors are lacking. Decisions on optimal first-line treatment must be based on analysis of relevant trials and consideration of various factors.

TRANSLATIONAL LUNG CANCER RESEARCH (2023)

Article Oncology

The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosis

Lisa Guccione, Karla Gough, Allison Drosdowsky, Timothy Price, Nick Pavlakis, David Wyld, David Ransom, Michael Michael, Penelope Schofield

Summary: This study identifies the healthcare preferences, patient experiences, and quality of life of patients with NETs at a 6-month follow-up. The research findings show that there are suboptimal experiences of care, such as low involvement in decision making and difficulties in accessing and understanding information. The study suggests that addressing these issues can improve patient care and quality of life.

SUPPORTIVE CARE IN CANCER (2023)

Article Medicine, Research & Experimental

Including migrant oncology patients in research: A multisite pilot randomised controlled trial testing consultation audio-recordings and question prompt lists

Amelia Hyatt, Ruby Lipson-Smith, Karla Gough, Phyllis Butow, Michael Jefford, Thomas F. Hack, Sandra Hale, Emiliano Zucchi, Shane White, Uldis Ozolins, Penelope Schofield

Summary: The study aimed to assess the feasibility of designing research inclusive of migrants who do not speak English. The results indicated that methods utilized in the study supported the inclusion of migrant oncology patients in research, and a future multi-site RCT efficacy assessment is feasible.

CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2022)

Review Medicine, General & Internal

Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer

L. B. Cameron, N. Hitchen, E. Chandran, T. Morris, R. Manser, B. J. Solomon, V Jordan

Summary: This study evaluated the safety and efficacy of ALK inhibitors as monotherapy for advanced ALK-rearranged NSCLC. The results showed that ALK inhibitors are effective in improving progression-free survival, overall survival, and overall response rate, with minimal adverse events compared to chemotherapy. Next-generation ALK inhibitors are more effective and safe than first-generation ALK inhibitors. However, further research is needed to compare different next-generation ALK inhibitors.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2022)

Article Endocrinology & Metabolism

Pitfalls and progress in adrenocortical carcinoma diagnosis: the utility of a multidisciplinary approach, immunohistochemistry and genomics

Ray Wang, Benjamin Solomon, Stephen J. Luen, Owen W. J. Prall, Christine Khoo, Anthony J. Gill, Jeremy Lewin, Nirupa Sachithanandan

Summary: Adrenocortical carcinoma is a rare disease with significant clinical heterogeneity, presenting a diagnostic challenge to clinicians. Specialist multidisciplinary team input and genomics play vital roles in diagnosis and prognosis of adrenocortical carcinoma.

ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS (2022)

暂无数据